| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Filing example | PancAlert (early-stage pancreatic cancer screening test) Pancreatic cancer | IND | — | RNA-Based Therapies | Oncology | ||
IND Filing example | PancAlert (early-stage pancreatic cancer screening test) Pancreatic cancer | IND | — | RNA-Based Therapies | Oncology | ||
IND Filing example | PancAlert (early-stage pancreatic cancer screening test) Pancreatic cancer | IND | — | RNA-Based Therapies | Oncology |
Recent Updates
Recently added Catalysts
Mainz Biomed N.V.$0.84
+0.04 (+5.07%)
F 9Pipeline Score Biotech · Clinical
Market Cap
7.65 M
EPS
-
P/E Ratio
-
Value Trade
4.82 M
3.32 %
Week
-11.15 %
1 Month
-21.84 %
3 Month
-50.05 %
6 Month
-99.85 %
5 Year
-99.85 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
5.25 M
52 Week Range
0.55 - 5.34
% held by Insiders
14.41 %
% held by Institutions
1.33 %
Enterprise Value
8.83 M
Total Shares
9.06 M
Short %
7.81 %
Float Shares
7.92 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F9
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 6%
Micro Cap (rank 852 of 905)
Percentile RankMainz Biomed N.V. has significant pipeline risk (9/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PancAlert | Pancreatic Cancer | Phase 1 | 2025-07-16 | |||
PancAlert | Pancreatic Cancer | Phase 1 | 2025-07-16 | |||
PancAlert | Pancreatic Cancer | Phase 1 | 2025-07-16 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MYNZ
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Mainz Biomed N.V. (MYNZ) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
MYNZ
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MYNZ
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MYNZ
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MYNZ Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MYNZ Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How MYNZ ranks across every disease it competes inCompetitive Position is a premium feature
See how MYNZ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial